Borosil Scientific Limited
Error: 'NoneType' object has no attribute 'get_text'
What Borosil files
- Others50
- Board Meeting14
- Important14
- PPTs4
- Updates3
- Credit Ratings2
Borosil Scientific's Q2FY26 consolidated sales rose 3.8% YoY to ₹106.9 Cr, while H1FY26 sales dipped 2.3% to ₹202.9 Cr. Profit after tax (PAT) saw a significant decline, with H1FY26 reporting a loss of ₹1.4 Cr. This was primarily due to a one-time VRS expense of ₹6.61 Cr and temporary operational...
Here is the summary based on the provided document: **Financial Highlights:** Q1FY26 consolidated net sales were ₹96.0 Cr (-8.2% YoY), with EBITDA at ₹7.8 Cr (-35.0% YoY) and a PAT loss of ₹4.2 Cr. This decline was primarily due to lower sales, an IND AS 115 accounting adjustment (₹2.59 Cr),...
1. Financial Highlights: Borosil Scientific reported consolidated net sales of ₹129.5 Cr for the quarter, rising 11.9% YoY, and ₹438.5 Cr for FY25, up 10.7%. Q4 EBITDA stood at ₹19.2 Cr with a 14.8% margin, slightly lower YoY, while FY25 EBITDA grew 19.2% to ₹60.4 Cr, improving margins to 13.8%....
**Financial Highlights**: Borosil Scientific reported a net sales increase to ₹101.5 Cr for Q3FY25, reflecting a 1.5% year-on-year growth. However, EBITDA decreased by 7.3% to ₹13.7 Cr, influenced by temporary production reductions in the Pharma Packaging segment, which affected margins. Year-to-date sales show an improvement of 10.2% compared to the...